Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

799 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial.
Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabrò P, Lupi A, Tomassini F, Cortese B, Rigattieri S, Cerrato E, Zavalloni D, Zingarelli A, Calabria P, Rubartelli P, Sardella G, Tebaldi M, Windecker S, Jüni P, Heg D, Valgimigli M. Sciahbasi A, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2017 May 23;69(20):2530-2537. doi: 10.1016/j.jacc.2017.03.018. Epub 2017 Mar 18. J Am Coll Cardiol. 2017. PMID: 28330794 Free article. Clinical Trial.
Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Campo G, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2006 Dec 5;48(11):2178-85. doi: 10.1016/j.jacc.2005.12.085. Epub 2006 Nov 13. J Am Coll Cardiol. 2006. PMID: 17161242 Free article.
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari R. Valgimigli M, et al. J Am Coll Cardiol. 2007 Jul 10;50(2):138-45. doi: 10.1016/j.jacc.2007.04.029. Epub 2007 May 22. J Am Coll Cardiol. 2007. PMID: 17616297 Free article. Clinical Trial.
Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study.
Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R. Campo G, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2007 Sep 18;50(12):1132-7. doi: 10.1016/j.jacc.2007.04.092. Epub 2007 Sep 4. J Am Coll Cardiol. 2007. PMID: 17868803 Free article.
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.
Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I. Lotrionte M, et al. Among authors: valgimigli m. Am J Cardiol. 2007 Oct 15;100(8):1199-206. doi: 10.1016/j.amjcard.2007.05.048. Epub 2007 Jul 30. Am J Cardiol. 2007. PMID: 17920357 Review.
Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry.
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Cook S, Reardon L, Moretti C, De Servi S, Palacios IF, Windecker S, Colombo A, van Domburg R, Sheiban I, Serruys PW; DELFT (Drug Eluting stent for LeFT main) Registry. Meliga E, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2008 Jun 10;51(23):2212-9. doi: 10.1016/j.jacc.2008.03.020. J Am Coll Cardiol. 2008. PMID: 18534266 Free article.
Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Marra S, Moretti C, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: valgimigli m. Int J Cardiol. 2009 Sep 11;137(1):16-21. doi: 10.1016/j.ijcard.2008.06.006. Epub 2008 Aug 6. Int J Cardiol. 2009. PMID: 18687481
A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai GG, Valgimigli M, Sheiban I, Margheri M, Marzocchi A, Prati F, Vischi M, Lettieri C, Violini R, Sardella G, Stabile A, Clementi F, Romeo F, Colombo A, Sangiorgi G. Biondi-Zoccai GG, et al. Among authors: valgimigli m. J Cardiovasc Med (Hagerstown). 2008 Sep;9(9):957-62. doi: 10.2459/JCM.0b013e3282ffd3a6. J Cardiovasc Med (Hagerstown). 2008. PMID: 18695440 Clinical Trial.
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: valgimigli m. EuroIntervention. 2008 May;4(1):77-83. doi: 10.4244/eijv4i1a14. EuroIntervention. 2008. PMID: 19112783
799 results